ImmunoCellular Therapeutics: Is There an Investment Case to be Made? (IMUC, $0.57)Tuesday, March 3, 2015 · 7:54 am |
|
ImmunoCellular Therapeutics LTD: Thoughts on Management’s Plan to Move ICT-107 into Phase 3 (IMUC, Neutral, $1.02)Tuesday, September 2, 2014 · 11:12 am |
|
ImmunoCellular; Thoughts on Its Plan to Move ICT-107 Forward into Phase 3 Trials Based on Data Presented at ASCO (IMUC, $1.34, Neutral, Free Content)Monday, June 2, 2014 · 9:57 am |
|
ImmunoCellular Has Plans to Move ICT-107 Forward into Phase 3 Trials; Should It? (IMUC, $1.19 Trading Buy, For Paid Subscribers)Wednesday, May 14, 2014 · 11:13 am |
|
The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)Friday, February 14, 2014 · 4:28 pm |
|
ImmunoCellular: Post Hoc Analysis of Disappointing Phase II Trial of ICT-107 (IMUC, $1.02)Sunday, December 15, 2013 · 11:37 am |
|
ImmunoCellular Thoughts on Potential Outcomes for the Phase II Trial of ICT-107 in Newly Diagnosed Glioblastoma (IMUC, $2.31) (Subscribers Only)Monday, November 11, 2013 · 11:40 am |
|
ImmunoCellular Therapeutics: A Close Look at Key Issues for the Ongoing Phase II Trial of ICT-107 (IMUC, $2.69)Wednesday, March 27, 2013 · 10:12 am |
|
Northwest Biotherapeutics and ImmunoCellular Therapeutics Can Both Be Winners with their Cancer Vaccines (NWBOD, $5.50)Friday, September 28, 2012 · 10:10 am |
|
The Rationale Behind Dendritic Cell-Based Cancer Vaccines and How They are Manufactured (NWBO.OB, $0.22)Thursday, April 26, 2012 · 6:24 am |
|
Initiation of Coverage of ImmunoCellular Therapeutics (IMUC.OB)Thursday, September 8, 2011 · 7:49 am |
|
|
There are 11 reports on file. |
